Nikko Asset Management Americas Inc. Buys 197,729 Shares of Guardant Health, Inc. (NASDAQ:GH)

Nikko Asset Management Americas Inc. grew its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 15.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,464,213 shares of the company’s stock after buying an additional 197,729 shares during the period. Nikko Asset Management Americas Inc.’s holdings in Guardant Health were worth $44,732,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. R Squared Ltd purchased a new stake in shares of Guardant Health in the 4th quarter worth about $26,000. SBI Securities Co. Ltd. purchased a new stake in Guardant Health during the 4th quarter valued at about $43,000. Kimelman & Baird LLC purchased a new stake in Guardant Health during the 4th quarter valued at about $58,000. Jones Financial Companies Lllp grew its position in Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock valued at $82,000 after purchasing an additional 817 shares during the last quarter. Finally, Van ECK Associates Corp grew its position in Guardant Health by 47.4% during the 4th quarter. Van ECK Associates Corp now owns 2,887 shares of the company’s stock valued at $88,000 after purchasing an additional 929 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Trading Up 5.5 %

NASDAQ GH opened at $42.89 on Monday. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $50.89. The company’s 50 day moving average is $43.01 and its two-hundred day moving average is $32.94. The stock has a market cap of $5.29 billion, a price-to-earnings ratio of -12.05 and a beta of 1.50.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $201.81 million for the quarter, compared to analysts’ expectations of $192.50 million. Sell-side analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently commented on GH shares. Stifel Nicolaus increased their price objective on shares of Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Guggenheim reissued a “buy” rating and set a $56.00 price objective on shares of Guardant Health in a research report on Monday, February 24th. JPMorgan Chase & Co. increased their price objective on shares of Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. The Goldman Sachs Group upped their target price on shares of Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Finally, Barclays initiated coverage on shares of Guardant Health in a research note on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price on the stock. Twenty equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Guardant Health has an average rating of “Buy” and a consensus price target of $48.40.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.